Netrin-1 and Placenta Accreta

The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04683562

Enrollment

Registered

2020-12-24

Start date

2021-12-01

Completion date

2022-06-01

Last updated

2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta

Brief summary

Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.

Interventions

OTHERPregnant women at 28-32 weeks

Pregnant women at gestational age 28-32 weeks

OTHERat delivery

women delivered at term

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Age between 20-40 years. * Singleton pregnancy. * Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping

Exclusion criteria

* Multiple pregnancy, * Fetal anomalies, * Preterm premature rupture of membranes, or infection * Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes * Patients with known bleeding disorders or on anticoagulant therapy.

Design outcomes

Primary

Measure	Time frame	Description
Placental Netrin-1 level	4 weeks	will be measured by using enzyme-linked immunosorbent assay (ELİSA) in placental homogenate

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026